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Abstract
One-stage and two-stage revision strategies are the two main options for treating established chronic peri-prosthetic joint
infection (PJI) of the hip; however, there is uncertainty regarding which is the best treatment option. We aimed to compare
the risk of re-infection between the two revision strategies using pooled individual participant data (IPD). Observational
cohort studies with PJI of the hip treated exclusively by one- or two-stage revision and reporting re-infection outcomes
were retrieved by searching MEDLINE, EMBASE, Web of Science, The Cochrane Library, and the WHO International
Clinical Trials Registry Platform; as well as email contact with investigators. We analysed IPD of 1856 participants with
PJI of the hip from 44 cohorts across four continents. The primary outcome was re-infection (recurrence of infection by the
same organism(s) and/or re-infection with a new organism(s)). Hazard ratios (HRs) for re-infection were calculated using
Cox proportional frailty hazards models. After a median follow-up of 3.7 years, 222 re-infections were recorded. Re-
infection rates per 1000 person-years of follow-up were 16.8 (95% CI 13.6–20.7) and 32.3 (95% CI 27.3–38.3) for one-
stage and two-stage strategies respectively. The age- and sex-adjusted HR of re-infection for two-stage revision was 1.70
(0.58–5.00) when compared with one-stage revision. The association remained consistently absent after further adjustment
for potential confounders. The HRs did not vary importantly in clinically relevant subgroups. Analysis of pooled individual
patient data suggest that a one-stage revision strategy may be as effective as a two-stage revision strategy in treating PJI of
the hip.
Keywords Prosthesis related infection  Total hip replacement  Reoperation  Revision  Re-infection  One-stage 
Two-stage  Meta-analysis
Introduction
Hip replacement is one of the most common surgical
procedures. In the UK, over 95,000 primary procedures
were performed in 2015 [1, 2]. In 2010, it was estimated
that 2.5 million Americans were living with a hip
replacement [3]. Peri-prosthetic joint infection (PJI) is a
serious adverse event affecting approximately one percent
of patients with a primary hip joint replacement [4] PJI has
a major negative effect on patients’ quality of life [5–7],
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and to avoid the need for excision arthroplasty or ampu-
tation, patients and their treating surgeons face complex
and protracted treatments.
In 1985, Fitzgerald and Jones described a series of two-
stage revisions for the treatment of infected hip implants
[8]. With this two-stage strategy, the artificial hip joint is
removed and replacement delayed for several months until
clear evidence of infection eradication is obtained. An
alternative one-stage revision procedure was in use from
1976 at the Endo-Klinik in Hamburg with the implant
removed and replaced in one operation [9]; however the
two-stage strategy has traditionally been considered the
gold standard for PJI treatment [10].
Given the absence of a robust randomised controlled
trial (RCT), the effectiveness of the two strategies have
been compared using aggregate data from case series
[11–13]. In the most recent review of 98 studies, we
reported 2-year re-infection rates of about 8% following
both one- or two-stage surgical revision for PJI of the hip
[14]. Our findings also showed that re-infection outcomes
were generally consistent for the revision strategies across
important patient characteristics and surgical factors. Some
features of our review limited the generalisability of the
findings. First, a detailed assessment of the definition of re-
infection could not be undertaken as this was not clearly
reported in the majority of studies. Second, our aim was to
include studies with at least 2 years of follow-up following
revision surgery, but this information was not always
available.
In the absence of robust evidence from a carefully
designed RCT, access to individual level data from pub-
lished studies could address the existing uncertainties and
enable: (1) a consistent approach to the definition of out-
comes; (2) a common approach across studies to statistical
analyses; and (3) improved generalisability through inclu-
sion of patients from key prospective studies worldwide.
In this context, we aimed to: (1) compare baseline and
clinical characteristics of patients undergoing one-stage
and two-stage revision surgery following PJI of the hip; (2)
compare the risk of re-infection between the two strategies;
and (3) examine the risk of re-infection according to a
range of clinically relevant characteristics. To achieve our
aims, we established the Global Infection Orthopaedic
Management (INFORM) collaboration. This international
consortium has allowed central collation and harmonisa-
tion of individual participant data (IPD) on 1856 patients
from 44 cohorts based in 13 different countries across 4
continents.
Methods
Data sources and search strategy
We conducted this systematic review and IPD pooled
analysis using a predefined protocol registered in the
PROSPERO International prospective register of system-
atic reviews (CRD42015016664) [15], and in accordance
with methods recommended by the IPD Meta-analysis
Methods Group of the Cochrane Collaboration [16], guid-
ance of Riley and colleagues [17], and the Preferred
Reporting Items for Systematic Reviews and Meta-Anal-
yses of Individual Participants Data (PRISMA-IPD)
guidelines [18] (see Appendix Supplement 1). We sought
IPD from studies identified through systematic searches of
MEDLINE, EMBASE, Web of Science, Cochrane Data-
base of Systematic Reviews, Cochrane Central Register of
Controlled Trials, and the WHO International Clinical
Trials Registry Platform from March 2011 (date of our
search for the previous review [13]) to February 2015 and
subsequently updated to August 2016. The computer-based
searches combined free text and medical subject headings
and combination of key words related to hip replacement,
infection, and revision with focus on one- and two-stage
surgeries. There were no restrictions on language. Studies
were also identified from reference lists of all retrieved
articles and other relevant publications, including reviews
and meta-analyses, and discussions with investigators of
unpublished studies. Further details on the search strategy
are presented in Appendix Supplement 2. No separate
ethical approval was required for the conduct of this study,
as any necessary ethical approval was obtained for each of
the individual studies contributing data to this pooled
analysis.
Eligibility criteria
Cohort studies were eligible if they met the following
inclusion criteria: (1) generally unselected patients with PJI
of the hip (i.e., patients’ representative of the general
patient population); (2) patients treated exclusively by one-
stage or two-stage revision; (3) and patients with at least
2 years of follow-up for re-infection outcomes. Peri-pros-
thetic joint infection was mainly diagnosed on the basis of
both the presence of clinical symptoms and the results of
microbiological culture from joint aspiration before sur-
gery and/or during surgery. Majority of studies defined PJI
based on diagnostic criteria proposed by the Muscu-
loskeletal Infection Society: positive joint fluid cultures,
joint fluid cell count and differentials, inflammatory
markers [C-reactive protein (CRP) and erythrocyte sedi-
mentation rate (ESR), presence of a sinus tract, gross
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purulence observed at the time of surgery, and a positive
histological exam for acute inflammation in tissues
obtained during surgery. Studies that reported case series of
methods in selected groups of patients (such as subsamples
of patients who received revision in one- or two-stages or
patients with a specific infection such as fungal infections)
were excluded from the review.
Global Infection Orthopaedic Management
(INFORM) collaboration
Details of the establishment of the Global INFORM col-
laboration have been reported previously in the published
protocol [15]. Briefly, investigators of eligible studies
identified by the literature search strategy and well-known
investigators in the field, were contacted by email or letter,
provided with a summary of the study protocol, and invited
to join the collaboration if they had the relevant data
available. Investigators expressing interest to collaborate in
this effort were then provided with full details of the study
protocol.
Data collection
Investigators were provided with a list of relevant study
variables that could be used in the analyses (Appendix
Supplement 3). Data from each study were obtained using a
standardised spreadsheet, and data dictionaries were also
requested. Details of contributing cohorts are presented in
Appendix Supplement 4. The raw data were examined and
inconsistencies or irregularities were clarified with the
investigators. Individual level data collected was coded and
entered into a single database. Additional studies were
included where useable data was tabulated in published
articles.
Outcome
The primary outcome variable was clinically diagnosed re-
infection, i.e. recurrence of infection by the same organ-
ism(s) and/or re-infection with a new organism(s). Patients
contributed only the first re-infection recorded after revi-
sion during follow-up. Outcomes were censored if a patient
was lost to follow-up.
Statistical analysis
Descriptive statistics were used to summarise baseline
characteristics according to the type of revision strategy.
We reported mean, standard deviation (SD), median, and
interquartile range (IQR) for continuous variables, and
proportions for categorical variables. The risks of re-in-
fection recorded during follow-up comparing the two-stage
with the one-stage (reference category) strategy were
assessed using Cox proportional shared frailty models [19],
after confirmation of no major departure from the propor-
tionality of hazards assumptions [20]. Because the treat-
ment variable (i.e. revision strategy) only varied between
studies/cohorts, inferences could only be made based on
differences in re-infection rates between studies using
either treatment strategy. A stratified Cox model was
therefore not suitable in this scenario as the ‘‘treatment
strategy’’ did not vary within studies. We employed a
shared frailty model, which is an extension of the Cox
proportional hazards model and provides a suitable way to
introduce random effects in the model to account for
unobserved heterogeneity. The random effect (the frailty)
has a multiplicative effect on the hazard function of a
cluster of individuals (cohort in this case). For each model,
we included a frailty term at the cohort level to allow for
dependence of individuals within each cohort. Survival
curves comparing the one- and two-stage strategies were
calculated using unadjusted Kaplan–Meier estimates and
compared using the log-rank test. Hazard ratios (HRs) with
95% confidence intervals (CIs) were calculated with pro-
gressive adjustment for age, sex, comorbidities (Charlson
comorbidity index [21]), previous hip surgery, and type of
infecting organism (‘‘difficult to treat versus ‘‘not difficult
to treat’’ [22, 23]; Appendix Supplement 5). These
covariates were selected on the basis of their role as
potential confounders and evidence from previous
research. Subgroup analyses were conducted using inter-
action tests to assess statistical evidence of any differences
in HRs across categories of pre-specified individual level
characteristics, specifically: sex, age group, previous hip
surgery, and type of infecting organism. A two-sided
P value less than 0.05 was considered statistically signifi-
cant throughout and all analyses were conducted using
Stata version 14 (StataCorp, College Station, Texas, USA).
Results
Study identification and selection
Figure 1 shows the inclusion and exclusion of studies. Our
systematic literature search identified 4344 potentially
relevant citations. After screening titles and abstracts, 59
articles remained for further evaluation. Following detailed
assessments, 35 articles were excluded. The remaining 24
articles (based on 28 unique studies) and 61 articles (based
on 70 unique studies) identified from our previous review
[13], were potentially eligible for the pooled analysis. Of
this number and in addition to three studies based on
unpublished data, we had access to individual level data
from 44 cohort studies. Overall, there were 13 one-stage
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and 31 two-stage studies based in 13 countries (from North
and South America, Europe, and Asia) (Appendix Sup-
plements 4 and 6).
Baseline and follow-up characteristics
Summary baseline and follow-up characteristics of the
1856 patients with PJI of the hip treated by one- or two-
stage revision that contributed to the analyses are shown in
Table 1. The mean (SD) age of overall participants at
baseline was 65 (13) years and 53% were men. A total of
884 patients received one-stage revision and 972 patients
received two-stage revision. The median (interquartile
range) follow up time was 4.2 (2.0–8.1) years in the one-
stage group and 3.3 (2.0–5.9) years in the two-stage group.
During follow-up, 88 (10.0%) participants experienced a
re-infection in the one-stage group compared with 134
(13.8%) in the two-stage group. Although the proportion of
men, mean BMI, proportion of patients having a previous
procedure to treat infection, and median baseline Harris
Hip Score (HHS) between the two treatment groups were
generally similar, several baseline characteristics and fol-
low-up data were not balanced between one- and two-stage
groups. The one-stage revision group had older patients on
average and had a higher proportion of patients with pre-
vious PJI and previous hip surgery (other than the index
surgery) compared with their two-stage counterparts. In
addition, the one-stage revision group had higher median
levels of baseline blood circulating CRP and a higher
proportion of patients presenting with an abscess, sinus,
draining wound, or fistula before revision. In the two-stage
group, a higher proportion of patients had a history of
diabetes and other comorbidities compared with one-stage
patients. The most common indication for the index
implantation for both groups was osteoarthritis. This was
followed by fractures in the one-stage group and
4344 Potentially relevant citations identified 
from March 2011:
4343 identified from databases
1 from manual scanning of reference list
4285 excluded on the basis of title 
and/ or abstract
35 excluded on the basis of:
14 selected patients
4 not revision relevant to review
3 selected two-stage
3 reviews
2 outcomes not relevant
2 patient population not relevant
2 articles not available
2 inadequate data with no response from authors
2 combined hip, knee, and shoulder data
1 duplicate24 articles comprising of 28 unique 
studies eligible for analyses
59 Full-text articles retrieved for more 
detailed evaluation
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analysis
47 articles excluded on basis of 
inability to contact authors, no 
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available from authors
Data contributed by 3 
unpublished studies
Fig. 1 Selection of studies included in the individual pooled data analysis
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Table 1 Summary of baseline characteristics and follow-up data in patients undergoing one- or two-stage revision
Overall One-stage revision Two-stage revision P value
Total number of participants 1856 884 972
Socio-demographic characteristics
Gender N = 1743 N = 864 N = 879 0.922
Males, n (%) 926 (53.1) 458 (53.0) 468 (53.2)
Females, n (%) 817 (46.9) 406 (47.0) 411 (46.8)
Age at baseline (years), mean (SD) 65.1 (13.0) 66.8 (12.4) 63.4 (13.3) \ 0.001
Smoking N = 365 N = 56 N = 309 0.151
Yes, n (%) 86 (23.6) 9 (16.1) 77 (24.9)
No, n (%) 279 (76.4) 47 (83.9) 232 (75.1)
History of high alcohol consumption N = 110 N = 0 N = 110
Yes, n (%) 6 (5.5) 6 (5.5)
No, n (%) 104 (94.6) 104 (94.6)
Physical measurements
N = 631 N = 269 N = 362
Body mass index in kg/m2, mean (SD) 27.6 (6.6) 27.5 (5.9) 27.8 (7.0) 0.580
Medical and surgical history
History of diabetes N = 803 N = 282 N = 521 0.028
Yes, n (%) 131 (16.3) 35 (12.4) 96 (18.4)
No, n (%) 676 (83.7) 247 (87.6) 425 (81.6)
History of hypertension N = 340 N = 157 N = 183 0.501
Yes, n (%) 119 (35.0) 52 (33.1) 67 (36.6)
No, n (%) 221 (65.0) 105 (66.9) 116 (63.4)
History of CVD N = 403 N = 161 N = 242 0.714
Yes, n (%) 99 (24.6) 38 (23.6) 61 (25.2)
No, n (%) 304 (75.4) 123 (76.4) 181 (74.8)
Comorbidity index N = 785 N = 282 N = 503 \ 0.001
No previously recorded disease categories, n (%) 256 (32.6) 45 (16.0) 211 (42.0)
One or two disease categories, n (%) 433 (55.2) 212 (75.2) 221 (43.9)
More than two disease categories, n (%) 96 (12.2) 25 (8.9) 71 (14.1)
History of previous PJI N = 321 N = 120 N = 201 \ 0.001
Yes, n (%) 62 (19.3) 47 (39.2) 15 (7.5)
No, n (%) 259 (80.7) 73 (60.8) 186 (92.5)
Previous hip surgery N = 1060 N = 809 N = 251 \ 0.001
Yes, n (%) 825 (77.8) 748 (92.5) 77 (30.7)
No, n (%) 235 (22.2) 61 (7.5) 174 (69.3)
Hip involved in index implantation N = 1233 N = 632 N = 601 0.863
Right, n (%) 676 (54.8) 348 (55.1) 328 (54.6)
Left, n (%) 557 (45.2) 284 (44.9) 273 (45.4)
Characteristics of infection before revision procedure
Previous procedure performed to treat infection N = 541 N = 277 N = 264 0.977
Yes, n (%) 137 (25.3) 70 (25.3) 67 (25.4)
No, n (%) 404 (74.7) 207 (74.7) 197 (74.6)
Presence of abscess, sinus, draining wound, or fistula at
presentation
N = 588 N = 278 N = 310 0.035
Yes, n (%) 160 (27.2) 87 (31.3) 73 (23.6)
No, n (%) 428 (72.8) 191 (68.7) 237 (76.5)
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osteonecrosis in the two-stage group (Fig. 2). The most
common cultured microorganism responsible for a PJI after
the index operation in the one-stage group was methicillin-
sensitive Staphylococcus (S.) aureus (MSSA); whereas it
was S. aureus or coagulase-negative staphylococci (CoNS)
in the two-stage group. Compared to the one-stage group,
there was a large percentage of negative cultures in the
two-stage group (Fig. 3). The median times to onset of
infection from index implantation and from infection to
revision surgery were longer in one-stage revision strategy
Table 1 (continued)
Overall One-stage revision Two-stage revision P value
Time from index implantation to infection (weeks), median
(IQR)
102.7 (36.6–299.2) 154.3 (51.4–350.1) 102.6 (32.6–268.5) 0.142
Time from infection to revision procedure (weeks), median
(IQR)
20.6 (8.4–51.4) 30.0 (10.2–94.2) 12.9 (6.4–34.3) \ 0.001
Baseline data before revision
C-reactive protein (mg/l), [N] median (IQR) [680] 18.9
(6.1–54.0)
[248] 22.5
(9.0–56.5)
[432] 17.1 (5.8–50.5) 0.052
Erythrocyte sedimentation rate (mm/h), [N] median (IQR) [371] 47 (26–73) [70] 41 (28–55) [301] 51 (25–76) 0.114
Neutrophils/ll, [N] median (IQR) [69] 4520
(2800–6000)
[23] 4800
(4100–6000)
[46] 3835 (99–5980) 0.044
WBC/ll, [N] median (IQR) [285] 7380
(6020–9090)
[178] 7100
(5920–8580)
[107] 8030
(6630–10860)
0.002
Harris Hip Score, [N] median (IQR) [171] 55.0
(48.0–60.0)
[12] 55.5
(43.5–63.5)
[159] 55–0
(480–60.0)
0.656
Characteristics of revision procedure and management
Type of re-implantation N = 122 N = 89 N = 33 0.201
Cemented, n (%) 91 (74.6) 65 (73.0) 26 (78.8)
Cementless, n (%) 23 (18.9) 16 (18.0) 7 (21.2)
Hybrid, n (%) 8 (6.6) 8 (9.0) 0 (0.0)
Antibiotics in cement N = 1092 N = 758 N = 334 \ 0.001
Yes, n (%) 750 (68.7) 584 (77.0) 166 (49.7)
No, n (%) 342 (31.3) 174 (23.0) 168 (50.3)
Nature of spacer used – – N = 293
Unknown, n (%) – – 2 (0.7)
Articulated, n (%) – – 287 (98.0)
Static, n (%) – – 4 (1.4)
Type of spacer – N = 183
Unknown, n (%) – – 1 (0.6)
Handmade, n (%) – – 167 (91.3)
Commercial, n (%) – – 15 (8.2)
Antibiotics in spacer – – N = 183
Yes, n (%) – 180 (98.4)
No, n (%) – 3 (1.6)
Duration between stages (weeks), median (IQR) – – 14.5 (11.0–24.0)
Duration of antibiotics use between stages (weeks), median
(IQR)
– – 24.0 (4.5–24.0)
After revision (follow-up)
Duration of antibiotic use after revision surgery (weeks),
median (IQR)
12.1 (6.1–12.6) 12.6 (12.0–12.6) 1.3 (0.5–5.5) \ 0.001
Duration of follow-up (years), median (IQR) 3.7 (2.0–6.9) 4.2 (2.0–8.1) 3.3 (2.0–5.9) \ 0.001
Harris Hip Score at follow up, median (IQR) 86.0 (73.0–93.0) 80.0 (52.0–90.0) 87.0 (78.0–95.0) 0.003
Number of re-infections 222 88 134
CVD cardiovascular disease, IQR interquartile range, MR methicillin resistant, MS methicillin sensitive, PJI periprosthetic joint infection, SD
standard deviation, WBC white blood cells
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patients compared with two-stage patients. The median
duration of antibiotic use after revision was considerable
longer in the one-stage group compared with the two-stage
group. However, the median duration of antibiotic therapy
between stages for the two-stage revision group was about
twice as long as after revision surgery in the one-stage
group. Thus, patients treated with two-stage revision
received a longer duration of antibiotics over the entire
course of treatment (median, 18.3 weeks) compared with
those treated with one-stage (median, 12.6 weeks).
Revision strategy and risk of re-infection
During a median (interquartile range) follow-up of 3.7
(2.0–6.9) years, 222 re-infections were recorded. Cumula-
tive hazard curves demonstrated a greater risk of re-in-
fection among two-stage revision strategy participants
compared with one-stage revision strategy participants
(P\ 0.001 for log-rank test; Fig. 4). Re-infection rates per
1000 person-years of follow-up across revision strategies
were 16.8 (95% CI 13.6–20.7) and 32.3 (95% CI
27.3–38.3) for the one-stage and two-stage strategies
respectively. Among 1038 individuals (113 re-infections)
with available survival data, comparing two- with one-
stage revision, the age-adjusted HR for re-infection was
1.69 (95% CI 0.58–4.98; P = 0.338). The corresponding
HR remained consistent 1.70 (95% CI 0.58–5.00;
P = 0.332) on adjusting for sex; and was attenuated to 1.33
(95% CI 0.48–3.69; P = 0.583) after further adjustment for
previous hip surgery (Table 2). The associations remained
absent in analyses restricted to 439 individuals (41 re-in-
fections) with available data on comorbidities and type of
infecting organism (Table 2). HRs did not vary importantly
by levels or categories of pre-specified patient level
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Fig. 2 Indications for index implantation by type of revision strategy
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Fig. 3 Type of infecting microorganism after index implantation by
type of revision strategy
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Table 2 Hazard ratios for re-
infection comparing two-stage
revision versus one-stage
revision adjusted progressively
for risk factors
Model Hazard ratio (95% CI) P value Hazard ratio (95% CI) P value
1038 participants
(113 re-infections)
with available data
439 participants
(41 re-infections)
with available data
Model 1 1.69 (0.58–4.98) 0.338 1.65 (0.44–620) 0.460
Model 2 1.70 (0.58–5.00) 0.332 1.66 (0.44–624) 0.454
Model 3 1.33 (0.48–3.69) 0.583 1.57 (0.45–551) 0.484
Model 4 – – 1.59 (0.39–655) 0.520
Model 5 – – 1.71 (0.39–750) 0.479
Model 1: adjusted for age
Model 2: model 1 plus sex
Model 3: model 2 plus previous hip surgery other than index surgery (yes/no)
Model 4: model 3 plus Charlson comorbidity index (no previous disease/one or two disease categories/more
than two disease categories)
Model 5: model 4 plus difficult to treat organism (yes/no)
Age at survey (years)
68
> 68
Sex
Female
Male
Previous hip surgery
No
Yes
Difficult to treat organism
No
Yes
Period of surgery
2000
> 2000
Both periods
Subgroup
248
247
198
297
234
261
369
126
19
385
91
No. of participants
21
27
18
30
32
16
31
17
6
34
8
No. of re-infections
1.38 (0.32, 6.02)
1.33 (0.35, 5.06)
1.08 (0.27, 4.37)
1.70 (0.46, 6.30)
2.26 (0.54, 9.41)
0.60 (0.10, 3.38)
1.22 (0.34, 4.42)
1.81 (0.43, 7.65)
1.84 (0.23, 14.98)
0.62 (0.27, 1.39)
1.84 (0.23, 14.98)
HR (95% CI)
.956
.464
.125
.530
.341
P-value*
.1 .25 .75 1 2.5 7.5 15 45
HR (95% CI) comparing two-stagewith one-stage
Fig. 5 Hazard ratios for re-infection by participant level character-
istics. Hazard ratios were adjusted for age, sex, previous hip surgery
other than index surgery (yes/no), and difficult to treat organism (yes/
no); CI confidence interval, HR hazard ratio; *P value for interaction.
Analysis was limited to 495 participants (comprising 48 re-infections)
with available data
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characteristics (P for interaction[ 0.10 for each) (Fig. 5).
In a post hoc subgroup analysis by period of surgery, there
was no statistically significant evidence of interaction.
Comment
Key findings
This large-scale study involving pooled analysis of indi-
vidual level data from 44 observational cohort studies was
conducted in an attempt to address the uncertainties
regarding the effectiveness of one-stage and two-stage
revision strategies for treating PJI of the hip, using re-
infection as the outcome of interest. With the exception of
average BMI, proportions of men and patients having a
previous procedure to treat infection, and median base-
line HHS, which were similar between the two treatment
groups; there were differences in baseline and follow-up
characteristics between one- and two-stage revision strat-
egy patients. Males were slightly overrepresented in both
treatment groups, a finding which was not unexpected
given that male sex is an established risk factor for PJI
[24, 25]. The proportions of patients with a previous hip
surgery other than the index surgery as well as a previous
PJI were higher in the one-stage revision strategy group
compared with the two-stage group. Patients in the one-
stage revision group seemed to have severe PJI at presen-
tation compared with the two-stage group, given their
higher levels of circulating CRP and higher proportion
presenting with an abscess, sinus, draining wound, or fis-
tula. These findings were unexpected, as patients with
severe PJI often undergo a two-stage revision to facilitate
additional antimicrobial strategies. Given the more limited
opportunities for antibiotic therapy associated with it, the
one-stage revision strategy has been traditionally thought
to expose patients to a higher risk of re-infection by
residual bacteria [26]; and it has been suggested this
strategy should only be used in selected cases, such as
patients with known organisms and sensitivities, non-im-
munocompromised patients, as well as absence of a sinus
tract [27, 28]. Our results also showed that MSSA was the
most commonly isolated microorganism responsible for a
PJI in the one-stage revision group. Compared with one-
stage revision patients, the two-stage group had a higher
proportion of patients with comorbidities. Staphylococcus
species were the most common causative organisms for PJI
in both treatment groups, results which are consistent with
the literature [23, 29, 30]. In addition, a large percentage of
two-stage patients had negative cultures compared with the
one-stage group, which reflects evidence that the one-stage
is commonly used in patients with known organisms and
sensitivities [27]. Results on the time to onset of infection
from index implantation suggested that a majority of PJIs
in the one-stage group were late infections (more than
24 months after surgery), while those of the two-stage
group were delayed infections (3–24 months after surgery)
[31]. Given that late infections are mostly acquired by
haematogenous seeding [23], this might account for the
severity of PJI in the one-stage revision group.
Unadjusted cumulative hazard curves suggested a higher
re-infection rate for the two-stage revision strategy com-
pared with one-stage revision; however, given the imbal-
ance between several baseline sociodemographic and
clinical characteristics, such unadjusted results are likely to
be confounded. In multivariate analyses, there was no
evidence of a statistically significant increased risk of re-
infection, when the two-stage revision strategy was com-
pared with the one-stage revision strategy. However, the
findings suggested there might be a higher risk of re-in-
fection in the two-stage revision group compared to the
one-stage group. The statistically non-significant associa-
tions remained consistent across clinically relevant sub-
groups. Given that the data collected for the current
analysis spanned the period 1971 through 2011 and which
might constitute a potential source of confounding for our
analyses, we conducted a subgroup analysis by period of
surgery and there was no evidence of effect modification
by period of surgery. However, there was a suggestion of a
protective effect for the period beyond the year 2000; a
finding which might reflect the adoption of improved sur-
gical strategies and use of newer and more effective
antimicrobial therapies in recent times compared to pre-
vious years. However, given the small samples in these
subgroups for analysis, further investigation is required.
Comparison with previous work
We are unable to directly compare the current findings with
previous work; because this is to our knowledge, the first
pooled analysis of individual level data from observational
cohort studies based in different countries that have
reported re-infection outcomes following one- or two-stage
surgical revision for infected hip prostheses. However, our
overall results, which suggest that the one-stage revision
strategy may be as effective as the two-stage revision
strategy in treating infected hip prostheses, seem to concur
and further extend that of previous aggregate reviews
conducted on the topic. In a review including 38 one-stage
and 60 two-stage revision strategy studies, we demon-
strated similar re-infection rates following one- or two-
stage surgical revision for infected hip prosthesis [14].
Other similar reviews have also reported findings which
suggest no significant superiority of either revision strategy
over the other. Leonard and colleagues in a review of nine
studies comparing re-infection rates between one- and two-
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stage revision strategies, reported that one-stage revision
was associated with similar re-infection rates when com-
pared with two-stage revision, and had superior functional
outcomes [32]. Lange and colleagues in a meta-analysis
involving 36 studies, reported results which indicated that
there were three additional re-infections per 100 patients
with infected hip prosthesis when a one-stage revision was
performed compared to a two-stage revision; however, the
risk estimates were imprecise with overlapping confidence
intervals, demonstrating no clear evidence of a superior
revision strategy [33].
Implications of findings
The current findings, as well as consistent findings from
several previous reviews, suggest that the one-stage revi-
sion strategy may be as effective as the two-stage strategy
in treating many patients with PJI of the hip. These results
are very relevant and may have clinical implications for
orthopaedic practice. For several decades, the two-stage
revision strategy has been presumed to be more effective
that the one-stage for treating PJIs [23, 34]. However, in
the absence of RCTs, several individual observational
cohorts, as well as reviews, have consistently failed to
show clear supportive evidence for the two-stage strategy
being more effective compared with the one-stage strategy.
Our finding of a null association is therefore not unex-
pected as it confirms speculations that the two revision
strategies may have comparable effectiveness for treating
PJI of the hip. In unadjusted analyses which employed the
entire sample in the dataset, there was statistically signifi-
cant evidence of an association between the two-stage
strategy and higher risk of re-infection. Therefore, it is
possible that our null results on multivariate analyses could
be attributed to low power, especially given the imprecise
estimates (wide confidence intervals). Although claimed to
be a more effective revision strategy, the two-stage strategy
has several drawbacks. In addition to the significant pain
and functional impairment, longer hospitalisation periods,
and increased risk of mortality associated with this strategy
[12, 34, 35], it is known to be associated with higher
healthcare costs compared to one-stage revision [36]. For
example, within the UK National Health System (NHS),
the cost of surgical revision of an infected hip replacement
is estimated to be about £22 000 [37]. A retrospective cost
analysis performed in a hospital in France estimated the
average cost (excluding social expenses) of a one-stage
revision for an infected total hip replacement to be €31
133, with a two-stage procedure costing 1.7 times more
than the one-stage alternative [36]. Furthermore, we have
shown that patients with two-stage revision also receive a
longer duration of antibiotics. There has been an increase
in the use of the one-stage revision strategy [38–40] after
its introduction several decades ago [9]. Despite the per-
ceived drawback of exposing patients to a higher risk of re-
infection by any residual bacteria [26], and the limited
opportunities for additional antibiotic therapy; the one-
stage strategy has major potential advantages for patients
which include the need for fewer surgical procedures,
shorter hospitalisation admissions, reduced duration of
antibiotic use, less time with functional limitation and
uncertainty, as well as economic benefits.
As a result of increasing life expectancy, there is a
growing healthcare burden due to osteoarthritis [41], which
will result in a projected increase in the numbers of primary
hip replacements as well as those requiring revision sur-
gery for PJI of the hip [42, 43]. Indeed, analysis of data for
England and Wales using the National Joint Registry
suggest that the volume of primary and revision hip
replacements will increase by 134 and 31%, respectively
between 2012 and 2030 [43]. Compared with primary hip
replacement procedures, the cost of revision surgery is
higher; with revision for PJI being more expensive than
aseptic revisions [37]. Given the high financial costs and
increased burden on resources associated especially with
the two-stage revision strategy, there is a need for opti-
misation of resources within the current economic climate.
The evidence suggests that the two revision strategies have
comparable effectiveness in the control of infection in
patients with peri-prosthetic hip infection. Our findings
also show that the one-stage strategy is an appropriate
treatment strategy for patients with characteristics that had
previously been thought to be inappropriate for one-stage
revision, such as those with sinus tracts at time of pre-
sentation. The overall findings suggest that the one-stage
strategy might be a preferable strategy for orthopaedic
surgeons performing revision surgeries for PJI of the hip.
Strengths and limitations of the study
Several strengths of this study merit consideration. We
have conducted the first pooled analysis of individual level
data from observational cohort studies comparing re-in-
fection rates among patients with PJI of the hip who have
undergone one- or two stage revision. Although previous
aggregate reviews conducted on the topic have included a
larger number of studies, the current analysis is unique in
the following ways: (1) compared with single-country
studies, our study pooled individual level data contributed
by study investigators across four continents which
enhanced generalisability of the findings; (2) there was a
more consistent approach to the definition of re-infection
outcomes; (3) it ensured that participants with at least
2 years of follow-up were included in the analyses; (4)
there was a common approach across studies to statistical
analyses; and (5) analyses included adjustment for relevant
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confounders which enabled reliable assessment of the
treatment effects, given the biases associated with unad-
justed results. Despite the novelty and strengths of the
current study, there are several limitations which deserve
consideration. A main limitation was that because the
revision strategy only varied between cohorts, a head-to-
head comparison of the two revision strategies could not be
made and appropriate inferences could only be made based
on differences in re-infection rates between studies using
either treatment strategy. However, given the clustered
nature of the survival data, we employed a shared frailty
Cox proportional model to account for any unobserved
heterogeneity. The majority of studies were unable to
contribute all relevant clinical data, which precluded
adjustment for a comprehensive panel of potential con-
founders, thereby introducing the possibility of residual
confounding. Given the sparcity of the data contributed by
different studies, multiple imputation was not considered;
as it is a challenging process in such situations and is
known to produce inaccurate imputations of the missing
values or does not appear to preserve relationships among
variables [44]. We were also unable to conduct detailed
analyses by clinically relevant subgroups such as type of
PJI (early vs delayed vs late), BMI, duration of antibiotic
therapy, and by population (geographical region) because
of the lack of data. Apart from the control of infection,
maintenance of joint function is also considered as an
important factor for a successful outcome following one- or
two stage revision [45, 46]. We were unable to compare the
two revision strategies using measures of joint function
such as the Western Ontario & McMaster Universities
Arthritis Index (WOMAC) Index, a validated patient-re-
ported outcome measure of hip pain, function and stiffness
widely used in joint replacement research [47]. A number
of qualitative studies (including one by our group) focusing
on outcomes after joint surgery, have shown that patients
are more concerned with pain and joint function (patient-
centred outcome measures) rather than clinical indices such
as re-infection rates [5, 48]. Because we included popula-
tions representative of patients in general clinical practice,
the results cannot be generalised to selected patient popu-
lations such as immunocompromised patients, culture
negative patients, and those with periprosthetic fungal
infections. The findings should therefore be interpreted in
context of the limitations available. Ideally, to compare the
effectiveness of these two revision strategies will require
evidence from a carefully designed RCT. However, given
the low incidence of PJI after total hip replacement, an
appropriate definitive RCT with re-infection as the primary
outcome may be unlikely in the short term. Lange and
colleagues report that a sample size of more than 3500
infected patients would be needed to investigate the supe-
riority of the two-stage over one-stage revision with
statistical precision, using re-infection as an outcome [33].
Within our INFection ORthopaedic Management
(INFORM) Programme, which is involved in developing
and establishing optimum management strategies for PJIs,
there is an ongoing trial to determine whether there is a
difference in patient-reported outcome measures (primary
outcome) between one-stage and two-stage revision surg-
eries for patients with PJI of the hip (INFORM; Current
controlled trials ISRCTN10956306) [49]. Results from this
study may help to elucidate and address differences in the
effectiveness of these two revision strategies.
In conclusion, analysis of pooled individual patient data
suggests that a one-stage revision strategy may be as
effective as a two-stage revision strategy in treating PJI of
the hip.
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